Compare e l f Beauty Inc (ELF) vs Moderna, Inc. (MRNA) Price & Performance

ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company shows robust revenue growth, expanding internationally with the rhode brand launch in Europe via Sephora, though net margins are thin at 3.38%. Valuation ratios are elevated with a P/E of 108.12, reflecting high growth expectations. Analyst consensus is mixed with a 48.27% buy rating but a price target of $95.91 below the current price.

Outlook: ELF's aggressive marketing and global expansion present growth opportunities, but the stock's premium valuation and high P/E pose risks if growth slows. Investor sentiment is cautiously optimistic, supported by institutional buying, yet overbought RSI levels suggest near-term volatility. Key risks include execution of international strategy and competitive pressures in the beauty sector.

Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.

Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.